Category Archives: Emerging Markets

US and Europe At Risk from Substandard Medicines

By Julian Upton | Published: February 25, 2010
Guest blog by Helen Disney, Chief Executive and Founder of the Stockholm Network, a pan-European think tank. When most of us look at taking a new medicine we tend to think it will make us better. Some of us may think about possible side effects but few of us expect the medicines we take to actually [...]
Also posted in Biotech, Europe, Global, Guest Blog, Regulatory, Safety | Tagged , , , , , , , , , , , | Leave a comment

Witty Proposes Price Cap for Poor Nations

By Cassandra Blohowiak | Published: February 18, 2009
GlaxoSmithKline CEO Andrew Witty proposed Friday to slash drug prices in the world’s 50 poorest countries and reinvest 20 percent of the profits in bolstering local health care. In a speech at Harvard Medical School Friday, Witty said drug prices will be capped at 25 percent of what they cost in developed nations. He also [...]
Also posted in Corporate Responsibility, People | Tagged , , , | Leave a comment

Gilead Making a Bundle

By Walter Armstrong | Published: February 10, 2009
Gilead Sciences has once again proven that independent biotechs can innovate with the best of Big Pharma. The Silicon Valley company’s wizardry at weaving multiple drugs into a single weft enabled it to overthrow GlaxoSmithKline as king of HIV in 2007. Yesterday, at the 16th annual Congress of Retroviruses and Opportunistic Infections (CROI), the biotech [...]
Also posted in Biotech, R&D | Tagged , , , | Leave a comment

Amid Big Pharma Woes, Shire in “Best Shape Ever”

By Joanna Breitstein | Published: November 17, 2008
Angus Russell, Shire’s longtime CFO—now CEO—likens the failing US automobile industry to pharma. “All the problems with the automobile industry were a long time coming,” he says. “It’s just that the SUVs and the relatively cheap price of gas created a bubble, just like a booming economy and blockbusters.” But now that the bubble has burst, [...]
Also posted in Deals, R&D, Strategy | Tagged , , | 1 Comment

The Real China Strategy

By Patrick Clinton | Published: August 12, 2008
There’s a lot of talk these days about India and China as potential markets and as sources for cheap manufacturing and R&D. But the real potential of these countries is far more interesting: As China and India (and Brazil, Russia, and Korea) learn to create new products, they’re going to do it at price [...]
Also posted in Biotech, Deals, Strategy | Tagged , , , , , | 8 Comments